Radiolabeled Peptides: Valuable Tools for the Detection and Treatment of Cancer
暂无分享,去创建一个
[1] V. Ambrosini,et al. Radiopeptide Imaging and Therapy in Europe , 2011, The Journal of Nuclear Medicine.
[2] F. Forrer,et al. Bombesin Antagonist–Based Radioligands for Translational Nuclear Imaging of Gastrin-Releasing Peptide Receptor–Positive Tumors , 2011, The Journal of Nuclear Medicine.
[3] R. Schibli,et al. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties. , 2011, Nuclear medicine and biology.
[4] W. Weber,et al. First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible , 2011, The Journal of Nuclear Medicine.
[5] W. Weber,et al. Novel 64Cu- and 68Ga-Labeled RGD Conjugates Show Improved PET Imaging of ανβ3 Integrin Expression and Facile Radiosynthesis , 2011, The Journal of Nuclear Medicine.
[6] Wolfgang A Weber,et al. PET of Somatostatin Receptor–Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference , 2011, The Journal of Nuclear Medicine.
[7] P. Ell,et al. Glucagon-Like Peptide-1 Versus Somatostatin Receptor Targeting Reveals 2 Distinct Forms of Malignant Insulinomas , 2011, The Journal of Nuclear Medicine.
[8] Matthias Briel,et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] L. Królicki,et al. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[10] A. Hubalewska-Dydejczyk,et al. 99mTc labeled GLP-1 scintigraphy with the use of [Lys40-(Ahx-HYNIC/EDDA)NH2]-Exendin-4 in the insulinoma localization , 2011 .
[11] W. Oyen,et al. Comparative biodistribution of 12 111In-labelled gastrin/CCK2 receptor-targeting peptides , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[12] R. Baum,et al. Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor. , 2011, Journal of medicinal chemistry.
[13] E. Krenning,et al. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[14] F. Forrer,et al. Targeted radiotherapy with radiolabeled somatostatin analogs. , 2011, Endocrinology and metabolism clinics of North America.
[15] S. Achilefu,et al. In Vitro and In Vivo Evaluation of 64Cu-Labeled SarAr-Bombesin Analogs in Gastrin-Releasing Peptide Receptor–Expressing Prostate Cancer , 2011, The Journal of Nuclear Medicine.
[16] S. Ametamey,et al. 18F-Labeled Bombesin Analog for Specific and Effective Targeting of Prostate Tumors Expressing Gastrin-Releasing Peptide Receptors , 2011, The Journal of Nuclear Medicine.
[17] Stephanie R. Lane,et al. Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model. , 2010, Nuclear medicine and biology.
[18] F. Pattou,et al. GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle. , 2010, The New England journal of medicine.
[19] B. Keil,et al. Exendin-4–Based Radiopharmaceuticals for Glucagonlike Peptide-1 Receptor PET/CT and SPECT/CT , 2010, Journal of Nuclear Medicine.
[20] Samantha V. Sublett,et al. Evaluation of [99mTc-(CO)3-X-Y-Bombesin(7-14)NH2] conjugates for targeting gastrin-releasing peptide receptors overexpressed on breast carcinoma. , 2010, Anticancer research.
[21] F. Forrer,et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[22] W. Oyen,et al. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[23] A. Nunn,et al. 177Lu-AMBA Biodistribution, Radiotherapeutic Efficacy, Imaging, and Autoradiography in Prostate Cancer Models with Low GRP-R Expression , 2009, Journal of Nuclear Medicine.
[24] F. Forrer,et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. , 2009, The Journal of clinical endocrinology and metabolism.
[25] S. Kneifel,et al. Evaluation of a 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid–Conjugated Bombesin-Based Radioantagonist for the Labeling with Single-Photon Emission Computed Tomography, Positron Emission Tomography, and Therapeutic Radionuclides , 2009, Clinical Cancer Research.
[26] Fan Wang,et al. 99mTcO(MAG2-3G3-dimer): a new integrin αvβ3-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[27] Fan Wang,et al. Noninvasive imaging of tumor integrin expression using 18F-labeled RGD dimer peptide with PEG4 linkers , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[28] E. Krenning,et al. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[29] Fan Wang,et al. 68Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin αvβ3 PET imaging , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[30] R. Schibli,et al. Influence of the molecular charge on the biodistribution of bombesin analogues labeled with the [99mTc(CO)3]-core. , 2008, Bioconjugate chemistry.
[31] S. Achilefu,et al. Preparation and Biological Evaluation of 64Cu-CB-TE2A-sst2-ANT, a Somatostatin Antagonist for PET Imaging of Somatostatin Receptor–Positive Tumors , 2008, Journal of Nuclear Medicine.
[32] Emanuel Christ,et al. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. , 2008, The New England journal of medicine.
[33] David A Mankoff,et al. Tumor Receptor Imaging , 2008, Journal of Nuclear Medicine.
[34] J. Burdette. In vivo imaging of molecular targets and their function in endocrinology. , 2008, Journal of molecular endocrinology.
[35] E. Krenning,et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] S. Jurisson,et al. 99mTc(CO)3-DTMA bombesin conjugates having high affinity for the GRP receptor. , 2008, Nuclear medicine and biology.
[37] C. Decristoforo,et al. 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of αvβ3 integrin expression , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[38] Eun Kyoung Ryu,et al. 18F-Labeled BBN-RGD Heterodimer for Prostate Cancer Imaging , 2008, Journal of Nuclear Medicine.
[39] R. Jensen,et al. Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states , 2008, Current opinion in endocrinology, diabetes, and obesity.
[40] Anastasia Nikolopoulou,et al. Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting , 2008, Journal of Nuclear Medicine.
[41] M. Essen,et al. et al Treatment with the radiolabeled somatostatinanalog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival Journal of Clinical Oncology : , 2008 .
[42] J. Correia,et al. A 99mTc(CO)3-labeled pyrazolyl–α-melanocyte-stimulating hormone analog conjugate for melanoma targeting , 2008 .
[43] D. Tourwé,et al. A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[44] Xiaoyuan Chen,et al. 68Ga-labeled multimeric RGD peptides for microPET imaging of integrin αvβ3 expression , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[45] Jason S. Lewis,et al. Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma. , 2007, Nuclear medicine and biology.
[46] Timothy J. Hoffman,et al. In Vivo Evaluation and Small-Animal PET/CT of a Prostate Cancer Mouse Model Using 64Cu Bombesin Analogs: Side-by-Side Comparison of the CB-TE2A and DOTA Chelation Systems , 2007, Journal of Nuclear Medicine.
[47] Peter Hohenberger,et al. 68Ga-Labeled Bombesin Studies in Patients with Gastrointestinal Stromal Tumors: Comparison with 18F-FDG , 2007, Journal of Nuclear Medicine.
[48] S. Figueroa,et al. [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues , 2007, Proceedings of the National Academy of Sciences.
[49] B. Nock,et al. [99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[50] S. Kneifel,et al. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor–Targeted Therapy for Insulinoma , 2007, Clinical Cancer Research.
[51] S. Gambhir,et al. Small-Animal PET of Melanocortin 1 Receptor Expression Using a 18F-Labeled α-Melanocyte-Stimulating Hormone Analog , 2007, Journal of Nuclear Medicine.
[52] Jason S. Lewis,et al. 64Cu-labeled CB-TE2A and Sar conjugated RGD peptide analogs for targeting angiogenesis: Comparison of their biological activity , 2007 .
[53] A. Beck‐Sickinger,et al. New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors. , 2007, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[54] W. Oyen,et al. αvβ3 Integrin‐targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide , 2007 .
[55] R. Valkema,et al. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours , 2007, Acta oncologica.
[56] L. Strauss,et al. 68 Ga-Labeled Bombesin Studies in Patients with Gastrointestinal Stromal Tumors: Comparison with 18 F-FDG , 2007 .
[57] Jason S. Lewis,et al. Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[58] M. Walter,et al. Influence of different spacers on the biological profile of a DOTA-somatostatin analogue. , 2007, Bioconjugate chemistry.
[59] W. Oyen,et al. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. , 2007, Nuclear medicine and biology.
[60] E. Krenning,et al. Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[61] T. Quinn,et al. 99mTc- and 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[62] F. Forrer,et al. Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[63] E. Krenning,et al. Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[64] W. Oyen,et al. Improved targeting of the αvβ3 integrin by multimerisation of RGD peptides , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[65] T. Visser,et al. Long-term toxicity of [177Lu-DOTA0,Tyr3]octreotate in rats , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[66] M. Eisenhut,et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[67] E. Krenning,et al. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[68] B. Keil,et al. A new technique for in vivo imaging of specific GLP-1 binding sites: First results in small rodents , 2006, Regulatory Peptides.
[69] P. Erba,et al. Receptor-mediated tumor targeting with radiolabeled peptides: there is more to it than somatostatin analogs. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[70] C Susini,et al. Rationale for the use of somatostatin analogs as antitumor agents. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[71] Martin Gotthardt,et al. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[72] C. Decristoforo,et al. [99mTc]HYNIC-RGD for imaging integrin αvβ3 expression , 2006 .
[73] Judit Erchegyi,et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors , 2006, Proceedings of the National Academy of Sciences.
[74] A. Hubalewska-Dydejczyk,et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[75] C. Punt,et al. Clinical applications of newer radionuclide therapies. , 2006, European journal of cancer.
[76] Raffaella Barone,et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. , 2006, Seminars in nuclear medicine.
[77] Klemens Scheidhauer,et al. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[78] W. Oyen,et al. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[79] Eduard Schreibmann,et al. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[80] G. Mariani,et al. Receptor radionuclide therapy of tumors: a road from basic research to clinical applications. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[81] W. Oyen,et al. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[82] T. Nayak,et al. 213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model , 2006, Clinical Cancer Research.
[83] B. Bernard,et al. Anticancer activity of targeted proapoptotic peptides. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[84] S. Denardo. Combined molecular targeting for cancer therapy: a new paradigm in need of molecular imaging. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[85] J. Parry,et al. MicroPET Imaging of Breast Cancer Using Radiolabeled Bombesin Analogs Targeting the Gastrin-releasing Peptide Receptor , 2006, Breast Cancer Research and Treatment.
[86] I. Virgolini,et al. Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[87] L. Strauss,et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[88] A. Grossman,et al. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. , 2005, Endocrine-related cancer.
[89] S. Gambhir,et al. microPET Imaging of Glioma Integrin αvβ3 Expression Using 64Cu-Labeled Tetrameric RGD Peptide , 2005 .
[90] R. Jensen,et al. Development of Simplified Vasoactive Intestinal Peptide Analogs with Receptor Selectivity and Stability for Human Vasoactive Intestinal Peptide/Pituitary Adenylate Cyclase-Activating Polypeptide Receptors , 2005, Journal of Pharmacology and Experimental Therapeutics.
[91] M. Béhé,et al. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[92] H. Ghandehari,et al. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[93] B. Bernard,et al. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[94] A. Eberle,et al. Melanoma targeting with DOTA-alpha-melanocyte-stimulating hormone analogs: structural parameters affecting tumor uptake and kidney uptake. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[95] E. Krenning,et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[96] Horst Kessler,et al. Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD , 2005, PLoS medicine.
[97] Martin A Walter,et al. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[98] H. Ohki‐Hamazaki,et al. Development and function of bombesin-like peptides and their receptors. , 2005, The International journal of developmental biology.
[99] E. Krenning,et al. Candidates for peptide receptor radiotherapy today and in the future. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[100] Marion de Jong,et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[101] R. Valkema,et al. Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. , 2005, Best practice & research. Clinical gastroenterology.
[102] T. Quinn,et al. -Melanocyte–Stimulating Hormone Peptide Analog in Murine and Human Melanoma-Bearing Mouse Models , 2004 .
[103] R. Valkema,et al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[104] E. Krenning,et al. Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[105] M. Pomper,et al. A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation. , 2005, Bioconjugate chemistry.
[106] M. Schwaiger,et al. [123I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with [111In]octreotide , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[107] J. Reubi,et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5 , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[108] S. Achilefu,et al. Preparation and Biological Evaluation of Copper-64–Labeled Tyr3-Octreotate Using a Cross-Bridged Macrocyclic Chelator , 2004, Clinical Cancer Research.
[109] B. Bernard,et al. Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[110] J. Reubi,et al. Synthesis and Evaluation of Bombesin Derivatives on the Basis of Pan-Bombesin Peptides Labeled with Indium-111, Lutetium-177, and Yttrium-90 for Targeting Bombesin Receptor-Expressing Tumors , 2004, Cancer Research.
[111] W. Oyen,et al. Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. , 2004, Cancer biotherapy & radiopharmaceuticals.
[112] M. Cremonesi,et al. A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[113] Horst Kessler,et al. First 18F-Labeled Tracer Suitable for Routine Clinical Imaging of sst Receptor-Expressing Tumors Using Positron Emission Tomography , 2004, Clinical Cancer Research.
[114] M. Cremonesi,et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[115] Subhani M Okarvi,et al. Peptide‐based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases , 2004, Medicinal research reviews.
[116] W. Oyen,et al. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. , 2004, Bioconjugate chemistry.
[117] L. Kvols,et al. Peptide receptor radionuclide therapy , 2005 .
[118] B. Van Den Bossche,et al. Receptor imaging in oncology by means of nuclear medicine: current status. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[119] M. Schwaiger,et al. First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.
[120] S. Mather,et al. Radiolabelling of peptides for diagnosis and therapy of non-oncological diseases. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[121] Franz Buchegger,et al. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[122] G. D. Vincentis,et al. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[123] J. Reubi. Peptide receptors as molecular targets for cancer diagnosis and therapy. , 2003, Endocrine reviews.
[124] E. Krenning,et al. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[125] H. Ulmer,et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[126] J. Reubi,et al. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[127] Donald L. Hayes,et al. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. , 2003, Nuclear medicine and biology.
[128] E. Nitzsche,et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[129] M. Schwaiger,et al. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[130] R. Valkema,et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[131] P. Angelberger,et al. New trends in peptide receptor radioligands. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[132] M. Béhé,et al. Imaging tumors with peptide-based radioligands. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[133] A. Beck‐Sickinger,et al. Peptides as carrier for tumor diagnosis and treatment. , 2001, Current medicinal chemistry. Anti-cancer agents.
[134] M. Thakur,et al. 99mTc labeled VIP analog: evaluation for imaging colorectal cancer. , 2001, Nuclear medicine and biology.
[135] T. Visser,et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives , 2001, European Journal of Nuclear Medicine.
[136] Shuang Liu,et al. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. , 2001, Bioconjugate chemistry.
[137] B. Wiedenmann,et al. Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours , 2000, European Journal of Nuclear Medicine.
[138] C. Beglinger,et al. Gastrin releasing peptide-preferring bombesin receptors mediate growth of human renal cell carcinoma. , 2000, Journal of the American Society of Nephrology : JASN.
[139] W. Scheithauer,et al. Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[140] J. Reubi,et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.
[141] T. Visser,et al. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0,TYR3]octreotide is dependent on the peptide amount , 1999, European Journal of Nuclear Medicine.
[142] J P Vincent,et al. Neurotensin and neurotensin receptors. , 1999, Trends in pharmacological sciences.
[143] J. Mueller‐Brand,et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment , 1998, The Lancet.
[144] P. Brooks,et al. Role of integrins in angiogenesis. , 1996, European journal of cancer.
[145] M. Mortrud,et al. Cloning and Functional Characterization of a Family of Receptors for the Melanotropic Peptides , 1993, Annals of the New York Academy of Sciences.
[146] H. Stein,et al. CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[147] Masayuki Masu,et al. Structure and functional expression of the cloned rat neurotensin receptor , 1990, Neuron.
[148] A. Eberle,et al. Characterization of Receptors for α-Melanocyte-stimulating Hormone on Human Melanoma Cells , 1989 .
[149] E. P. Krenning,et al. LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN , 1989, The Lancet.
[150] A. Eberle,et al. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. , 1989, Cancer research.
[151] S. Bloom,et al. Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. , 1978, Gut.